Herein, we review the current knowledge on the use of IL-15 as a cancer therapy, with a particular focus on the mechanism(s) of action and preclinical and clinical development of N803 (Anktiva®, formerly known as ALT803), an IL-15 heterodimeric agonist. The gene discussed is IL15; the disease is cancer.